AC Immune (ACIU) Stock Price, News & Analysis

Company Overview

AC Immune AG (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on the discovery and development of therapies for Alzheimer’s disease and other neurodegenerative disorders. The company leverages two proprietary technology platforms—Morphomer™ for small-molecule therapies and SupraAntigen™ for antibody and vaccine development—to target misfolded proteins implicated in conditions such as Alzheimer’s, Parkinson’s and Creutzfeldt-Jakob disease.

The firm’s pipeline includes multiple clinical-stage assets designed to address both amyloid-beta and tau pathologies. Lead programs include antibody candidates in collaboration with global partners and a proprietary tau vaccine in Phase 2 development. Preclinical efforts extend to novel small molecules aimed at inhibiting toxic protein aggregation, with the goal of modifying disease progression rather than solely treating symptoms.

Since its founding in 2003, AC Immune has established collaborations with major biopharma companies to co-develop and commercialize its therapeutic candidates. The company maintains research facilities in Switzerland and the United States, enabling seamless integration of discovery, translational and clinical activities across geographies. Partnerships have provided access to complementary expertise, regulatory support and global development networks.

AC Immune is led by a management team of seasoned industry professionals, spearheaded by co-founder and Chief Executive Officer Andrea Pfeifer. The board of directors and scientific advisory panels bring extensive experience in neuroscience, drug development and regulatory affairs. Through its dual‐platform approach, AC Immune aims to deliver novel treatments that can alter the course of devastating neurodegenerative diseases.

Key Stats

• Today's Range: $2.03 to $2.11
• 50-Day Range: $1.53 to $2.20
• 52-Week Range: $1.43 to $4.26
• Volume: 86,216 shs
• Average Volume: 143,134 shs
• Market Capitalization: $204.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

AC Immune Stock Analysis - MarketRank™

AC Immune scored higher than 45% of companies evaluated by MarketBeat, and ranked 636th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

AC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

AC Immune has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AC Immune are expected to grow in the coming year, from ($0.62) to ($0.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AC Immune is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AC Immune is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AC Immune has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.31% of the float of AC Immune has been sold short.

Short Interest Ratio / Days to Cover

AC Immune has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.

Change versus previous month

Short interest in AC Immune has recently increased by 3.68%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AC Immune does not currently pay a dividend.

Dividend Growth

AC Immune does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.31% of the float of AC Immune has been sold short.

Short Interest Ratio / Days to Cover

AC Immune has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.

Change versus previous month

Short interest in AC Immune has recently increased by 3.68%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 1.74

News Sentiment

AC Immune has a news sentiment score of 1.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for AC Immune this week, compared to 1 article on an average week.

Search Interest

3 people have searched for ACIU on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AC Immune insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of AC Immune is held by insiders.

Percentage Held by Institutions

51.36% of the stock of AC Immune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACIU Stock Analysis - Frequently Asked Questions

How have ACIU shares performed this year?

AC Immune's stock was trading at $2.70 on January 1st, 2025. Since then, ACIU shares have decreased by 24.4% and is now trading at $2.04.

How were AC Immune's earnings last quarter?

AC Immune (NASDAQ:ACIU) released its quarterly earnings results on Wednesday, April, 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01. The business had revenue of $1.12 million for the quarter, compared to the consensus estimate of $1.99 million. AC Immune had a negative trailing twelve-month return on equity of 44.60% and a negative net margin of 177.79%.

When did AC Immune IPO?

AC Immune (ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

How do I buy shares of AC Immune?

Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AC Immune own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AC Immune investors own include Meta Platforms (META), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Tesla (TSLA), Advanced Micro Devices (AMD) and Canopy Growth (CGC).

Company Calendar

• Last Earnings: 4/30/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACIU
• CIK: 1651625
• Web: www.acimmune.com
• Phone: (121) 345-9121
• Fax: 41-21-345-9120
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Price Target for AC Immune: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +488.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.83 million
• Net Margins: -177.79%
• Pretax Margin: -179.67%
• Return on Equity: -44.60%
• Return on Assets: -22.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.53
• Quick Ratio: 1.53

Sales & Book Value

• Annual Sales: $31.02 million
• Price / Sales: 6.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.29 per share
• Price / Book: 1.58

Miscellaneous

• Outstanding Shares: 100,410,000
• Free Float: 95,791,000
• Market Cap: $204.84 million
• Optionable: Optionable
• Beta: 1.62